[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100522234","confocal-laser-endomicroscopy-verification-100522234",false,"NCT06079970","Confocal Laser Endomicroscopy VERification","Bronchoscopy With and Without Needle-based Confocal Laser Endomicroscopy for Peripheral Lung Nodule Diagnosis: Protocol for a Multicenter Randomized Controlled Trial (CLEVER Trial)","CLEVER","Inclusion Criteria:\n\n1. ≥18 years of age\n2. Suspected malignant peripheral lung lesion with an indication for a bronchoscopic diagnostic work-up as determined by the attending physician or tumor board. Peripheral pulmonary lesions are defined as lesions located beyond the visible segmental bronchi, not detectable by regular flexible bronchoscopy\n3. Bronchus sign on pre-procedural CT or estimated confidence for successful navigation to the nodule resulting in a r-EBUS signal\n4. Solid part of the lesion must be ≧10 mm\n5. Largest dimension of lesion size on CT ≦30 mm (long-axis)\n6. Ability to understand and willingness to sign a written informed consent\n\nExclusion Criteria:\n\n1. Inability or non-willingness to provide informed consent\n2. Endobronchial visible malignancy on bronchoscopic inspection\n3. Target lesion within reach of the linear EBUS scope\n4. Failure to comply with the study protocol\n5. Known allergy or risk factors for an allergic reaction to fluorescein\n6. Pregnancy or breastfeeding\n7. Hemodynamic instability\n8. Refractory hypoxemia\n9. Therapeutic anticoagulant use that cannot be withheld for an appropriate interval before the procedure\n10. Unable to tolerate general anesthesia according to the anesthesiologist\n11. Undergoing chemotherapy as several chemotherapies have fluorescent properties at the same wavelength (e.g., doxorubicin)","ALL","18 Years",{"count":20,"type":21},208,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this multi-center randomized clinical trial is to evaluate the added value of needle based confocal laser endomicroscopy (nCLE)-imaging to regular diagnostic bronchoscopic peripheral lung lesion analysis on the diagnostic yield in patients with peripheral pulmonary nodules suspect for malignancy.\n\nThe main question\\[s\\] it aims to answer are:\n\nTo determine if the addition of nCLE-imaging to conventional diagnostic bronchoscopic peripheral lung lesion analysis results in an improved diagnostic yield (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis out of the total number of patients that have received the diagnostic bronchoscopic procedure).\n\nParticipants will undergo diagnostic bronchoscopy either with or without the addition of nCLE imaging before each TBNA. Based on the feedback of the CLE images on (in)correct placement of the needle, the needle might be repositioned before sampling. Comparison between the diagnostic yield of these groups will be done including subgroup analysis.",[27,28,29,30],"Lung Cancer","Lung Neoplasm Malignant","Carcinoma, Non-Small-Cell Lung","Neoplasm of Lung",[32,33,34,35,36],"Confocal Microscopy","Bronchoscopy","Confocal laser endomicroscopy","CLE","Fluoroscopy","RECRUITING","2026-04-01",{"date":40,"type":41},"2026-04-07","ACTUAL",{"date":43,"type":41},"2023-10-18",{"date":45,"type":21},"2026-12-31",{"name":47,"class":48},"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)","OTHER",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100529826","towards-novel-biomarkers-to-diagnose-sepsis-on-the-emergency-room-100529826","NCT06178822","Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room","BIOSEP","Inclusion Criteria:\n\n* Age 18 years or higher\n* Presentation at the Emergency Department (ED)\n* Clinical suspicion of infection or earlier confirmed infection\n* Modified Early Warning Score (MEWS) of 2 or higher\n\nExclusion Criteria:\n\n* No informed consent given",{"count":58,"type":21},3300,"1 Year","OBSERVATIONAL","Objectives:\n\n1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection.\n2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis.\n3. To determine the long term cognitive and physical sequelae of sepsis after admission.",[63,64,65,66,67,68,69],"Sepsis","Septic Shock","Sepsis, Severe","Infections","Infection Viral","Infection, Bacterial","Infections, Respiratory",[71,72,73,74],"Biomarkers","Emergency Room","A&E","Accident & Emergency","2025-09-29",{"date":77,"type":41},"2025-10-02",{"date":79,"type":41},"2022-10-25",{"date":81,"type":21},"2026-10-01",{"name":47,"class":48},3,""]